Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

EU Application Filed for Daratumumab in Newly Diagnosed, Transplant-Eligible Myeloma

March 27th 2019

A Type II variation application has been submitted to the European Medicines Agency for the 4-drug regimen of daratumumab, bortezomib, thalidomide, and dexamethasone as a treatment for patients with newly diagnosed multiple myeloma who are eligible to undergo autologous stem cell transplant.

FDA Approval Sought for Frontline Daratumumab Regimen in Transplant-Eligible Myeloma

March 26th 2019

A supplemental biologics license application has been submitted to the FDA for daratumumab in combination with bortezomib, thalidomide, and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.

Emerging Treatments in Multiple Myeloma Spark Prospect for Cure

March 26th 2019

James E. Hoffman, MD, discusses the current treatment options available for patients with multiple myeloma, underscores remaining challenges in the space, and shares predictions for where the field is headed.

EU Approval Sought for Frontline Daratumumab/Rd in Transplant-Ineligible Myeloma

March 23rd 2019

A Type II variation application has been submitted to the European Medicines Agency for the combination of daratumumab with lenalidomide and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation.

BCMA Antibody-Drug Conjugate Continues to Extend PFS in Relapsed/Refractory Myeloma

March 22nd 2019

The investigational antibody-drug conjugate GSK2857916 continued to improve progression-free survival in patients with relapsed/refractory multiple myeloma, according to results of a final analysis of the DREAMM-1 study.

Dr. Cho on Promising Combinations in Multiple Myeloma

March 20th 2019

Hearn Jay Cho, MD, PhD, associate professor of medicine, Hematology/Oncology, Icahn School of Medicine, Mount Sinai Hospital, discusses promising combinations in multiple myeloma.

Dr. Holstein on BiTEs in Multiple Myeloma

March 19th 2019

Sarah Holstein, MD, PhD, associate professor of medicine, University of Nebraska Medical Center, discusses the emergence of bispecific T-cell engagers (BiTEs) in multiple myeloma.

FDA Halts Enrollment on Venetoclax Myeloma Trials

March 19th 2019

The FDA has placed a partial clinical hold on all clinical trials examining venetoclax in multiple myeloma, halting enrollment of new patients on the studies.

Dr. Berdeja Discusses Anticipated Research in Multiple Myeloma

March 19th 2019

Jesus Berdeja, MD, the director of Multiple Myeloma Research at Sarah Cannon Research Institute, discusses anticipated research in the field of multiple myeloma.

Usmani Elucidates Management of Early Relapse in Multiple Myeloma

March 18th 2019

Saad Z. Usmani, MD, shares insight on approaches to early relapse in myeloma given the evolution of frontline treatment advances.

FDA Extends Review Period for Selinexor in Myeloma

March 15th 2019

The FDA has added 3 months to the review period for a new drug application for selinexor for the treatment of patients with penta-refractory multiple myeloma, making the new action date July 6, 2019.

Allogeneic HSCT Retains Role in Relapsed Myeloma

March 15th 2019

Sergio A. Giralt, MD, discusses recent data with allogeneic hematopoietic stem cell therapy and why this long-standing modality remains an integral part of treatment for patients with relapsed myeloma.

Dr. Usmani on Management of Early Relapse in Multiple Myeloma

March 13th 2019

Saad Z. Usmani, MD, FACP, chief of Plasma Cell Disorder, director of Clinical Research in Hematologic Malignancies, Levine Cancer Institute, Atrium Health, discusses the management of early relapse in multiple myeloma.

Rolling Submission Completed for Daratumumab/Rd in Frontline Transplant-Ineligible Myeloma

March 13th 2019

A supplemental biologics license application has been submitted to the FDA for the approval of daratumumab in combination with lenalidomide and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

Creating Lasting Benefit With CAR T-Cell Therapy in Myeloma

March 11th 2019

Noopur Raje, MD, discusses the current treatment landscape of multiple myeloma, with a specific focus on available triplet regimens and the recent data with chimeric antigen receptor T-cell therapy.

Dr. Holstein on Recent Data With Venetoclax in Myeloma

March 9th 2019

Sarah Holstein, MD, PhD, associate professor of medicine, University of Nebraska Medical Center, discusses recent data with venetoclax in the treatment of patients with myeloma.

Dr. Lonial on Treatment of Patients With Late Relapse Myeloma

March 7th 2019

Sagar Lonial, MD, professor and chair, Department of Hematology and Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses the treatment of patients with late relapse myeloma.

Agents Emerging in Late Relapsed/Refractory Myeloma Space

March 3rd 2019

Sagar Lonial, MD, discusses some of the emerging agents for the treatment of patients with late relapse in multiple myeloma.

Dr. Usmani Discusses Management of Early Relapse in Myeloma

March 2nd 2019

Saad Z. Usmani, MD, FACP, shares his advice for the management of early relapse in patients with multiple myeloma.

Dr. Chari Discusses Frail and Elderly Patients With Multiple Myeloma

March 2nd 2019

Ajai Chari, MD, associate professor, Icahn School of Medicine, Mount Sinai Health System, discusses frail and elderly patients with multiple myeloma.